35 related articles for article (PubMed ID: 16503086)
1. Adverse Effects of Gefitinib on Skin and Colon in a Lung Cancer Mouse Model.
Wang Y; Cheng S; Zhang H; Zhang Y; Ding C; Peng T; Chen W; Yang K; Zhang J; Tan Y; Wang X; Liu Z; Wei P; Jiang M; Hua Q
Recent Pat Anticancer Drug Discov; 2024; 19(3):308-315. PubMed ID: 37723963
[TBL] [Abstract][Full Text] [Related]
2. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma.
Uysal M; Beypinar I; Araz M
J Cancer Res Ther; 2024 Jan; ():. PubMed ID: 38261436
[TBL] [Abstract][Full Text] [Related]
3. Lung spindle cell carcinoma harbouring a constitutively active epidermal growth factor receptor mutation.
Ikushima H; Sakatani T; Masuda Y; Morikawa T; Usui K
Respirol Case Rep; 2019 Feb; 7(2):e00395. PubMed ID: 30555702
[TBL] [Abstract][Full Text] [Related]
4. Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report.
Bian S; Tang X; Ye S; Lei W
Respir Med Case Rep; 2020; 31():101228. PubMed ID: 32995264
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy.
Sugiura Y; Nemoto E; Kawai O; Ohkubo Y; Fusegawa H; Kaseda S
Lung Cancer (Auckl); 2013; 4():9-14. PubMed ID: 28210130
[TBL] [Abstract][Full Text] [Related]
6. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
7. [Drug induced hepatotoxicity in targeted therapy for lung cancer].
Chen X; Yang S; Ma S
Zhongguo Fei Ai Za Zhi; 2014 Sep; 17(9):685-8. PubMed ID: 25248711
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
9. Safety of gefitinib in non-small cell lung cancer treatment.
Hsiue EH; Lee JH; Lin CC; Yang JC
Expert Opin Drug Saf; 2016 Jul; 15(7):993-1000. PubMed ID: 27212579
[TBL] [Abstract][Full Text] [Related]
10. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
[TBL] [Abstract][Full Text] [Related]
11. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
[TBL] [Abstract][Full Text] [Related]
13. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
14. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
15. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
Yoshida K; Yatabe Y; Park JY; Shimizu J; Horio Y; Matsuo K; Kosaka T; Mitsudomi T; Hida T
J Thorac Oncol; 2007 Jan; 2(1):22-8. PubMed ID: 17410005
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
